Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2006 Nov 17;20(6):260–265. doi: 10.1002/jcla.20152

Proinflammatory cytokine gene polymorphisms among Hashimoto's thyroiditis patients

Rong‐Hsing Chen 1, Chwen‐Tzuei Chang 1, Wei‐Chi Chen 2,3, Chang‐Hai Tsai 4,5, Fuu‐Jen Tsai 3,4,✉
PMCID: PMC6807634  PMID: 17115419

Abstract

Proinflammatory cytokines are involved in the pathogenesis of Hashimoto's thyroiditis (HT). To test whether certain specific proinflammatory cytokine gene polymorphisms could be genetic markers for an individual's susceptibility to HT, we investigated single‐site polymorphisms of certain proinflammatory cytokine genes of interest for 107 HT sufferers and 163 controls, subsequent to preparing the necessary experimental genomic DNA from peripheral blood, using a polymerase chain reaction (PCR)‐based restriction analysis. The polymorphisms we detected were as follows: 1) C/T and E1/E2 polymorphisms for the interleukin (IL)‐1β gene at promoter (−511) and exon 5, respectively; 2) a variable number of tandem repeats (VNTRs) for the IL‐1 receptor antagonist (IL‐1Ra) gene at intron 2; 3) a C/G polymorphism for the IL‐6 gene at promoter (−572); and 4) an A/G polymorphism for the tumor necrosis factor (TNF)‐α gene at promoter (−308). The data demonstrated an increased ratio of CG genotype and decreased ratios of CC and GG genotypes (chi‐squared test; P = 0.025) for the IL‐6 gene promoter for HT patients when compared with normal controls. The odds ratio (OR) for the CG genotype, as compared to the GG genotype, for HT patients was shown to be 4.065 (95% confidence interval (CI): 1.268–13.032). Comparison of the genotype analysis for the remaining gene polymorphisms and the allelic analysis for all of the screened gene polymorphisms, however, all revealed no statistically significant difference between the two study groups as regards frequency of genotype. In conclusion, we suggest that an IL‐6 gene promoter (−572) C/G polymorphism could represent a potential “candidate” genetic marker to predict an individual's susceptibility to HT. J. Clin. Lab. Anal. 20:260–265, 2006. © 2006 Wiley‐Liss, Inc.

Keywords: Hashimoto's thyroiditis, polymorphism, proinflammatory cytokine

REFERENCES

  • 1. Doniach D. Hashimoto's thyroiditis and primary myxedema viewed as separate entities. Eur J Clin Invest 1981;11:245–246. [DOI] [PubMed] [Google Scholar]
  • 2. Woolner LB, McConahey WM, Beahrs OH. Struma lymphomatosa [Hashimoto's thyroiditis] and the related thyroidal disorder. J Clin Endocrinol Metab 1959;19:53–83. [DOI] [PubMed] [Google Scholar]
  • 3. Martin A, Davies TF. T cells and human autoimmune thyroid disease: emerging data show lack of need to invoke suppressor T‐cell problem. Thyroid 1992;2:247–261. [DOI] [PubMed] [Google Scholar]
  • 4. Weetman AP. Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol 2003;148:1–9. [DOI] [PubMed] [Google Scholar]
  • 5. Giordano C, Stassi G, De Maria R, et al. Potential involvement of fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science 1997;275:960–963. [DOI] [PubMed] [Google Scholar]
  • 6. Chiovato L, Bassi P, Santini F, et al. Antibodies producing complement‐mediated thyroid cytotoxicity in patients with atrophic or goitrous autoimmune thyroiditis. J Clin Endicrinol Metab 1993;77:1700–1705. [DOI] [PubMed] [Google Scholar]
  • 7. Kelso A. Cytokines: principles and prospects. Immunol Cell Biol 1998;76:300–317. [DOI] [PubMed] [Google Scholar]
  • 8. Rosenwasser LJ. Biologic activities of IL‐1 and its role in human disease. J Allergy Clin Immunol 1998;102:344–350. [DOI] [PubMed] [Google Scholar]
  • 9. Kopf M, Le Gros G, Coyle AJ, Kosco‐Vilbois M, Brombacher F. Immune responses of IL‐4, IL‐5, IL‐6 deficient mice. Immunol Rev 1995;148:45–69. [DOI] [PubMed] [Google Scholar]
  • 10. Kissonerghis AM, Grubeck‐Loebenstein B, Feldmann M, Londei M. Tumour necrosis factor synergises with gamma interferon on the induction of mRNA for DR alpha chain on thyrocytes from Graves' disease and non toxic goitre. Autoimmunity 1989;44:255–266. [DOI] [PubMed] [Google Scholar]
  • 11. Weetman AP. Autoimmune thyroiditis: predisposition and pathogenesis. Clin Endocrinol (Oxf) 1992;36:307–323. [DOI] [PubMed] [Google Scholar]
  • 12. Wan XL, Kimura Dong RP, Honda K, Tamai H, Sasazuki T. HLA‐A and DRB4 genes in controlling the susceptibility to Hashimoto's thyroiditis. Hum Immunol 1995;42:131–136. [DOI] [PubMed] [Google Scholar]
  • 13. Yanagawa T, Taniyama M, Enomoto S, et al. CTLA4 gene polymorphism confers susceptibility to Graves' disease in Japanese. Thyroid 1997;7:843–846. [DOI] [PubMed] [Google Scholar]
  • 14. Bougacha‐Elleuch N, Rebai A, Mnif M, et al. Analysis of MHC genes in a Tunisian isolate with autoimmune thyroid diseases: implication of TNF –308 gene polymorphism. J Autoimmun 2004;23:75–80. [DOI] [PubMed] [Google Scholar]
  • 15. Chen RH, Chen WC, Chang CT, Tsai CH, Tsai FJ. Interleukin‐1‐beta gene, but not the interleukin‐1 receptor antagonist gene, is associated with Graves' disease. J Clin Lab Anal 2005;19:133–138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Cantagrel A, Navaux F, Loubet‐Lescoulie P, Nourhashemi F, Enault G, Abbal M. Interleukin‐1β, interleukin‐1 receptor antagonist, interleukin‐4, and interleukin‐10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999;42:1093–1100. [DOI] [PubMed] [Google Scholar]
  • 17. Chung HW, Seo JS, Hur SE, et al. Association of interleukin‐6 promoter variant with bone mineral density in pre‐menopausal women. J Hum Genet 2003;48:243–248. [DOI] [PubMed] [Google Scholar]
  • 18. Galbraith GM, Pandey JP. Tumor necrosis factor alpha (TNF‐α) gene polymorphism in alopecia areata. Hum Genet 1995;96:33–436. [DOI] [PubMed] [Google Scholar]
  • 19. Taga T, Kawanishi Y, Hardy RR, Hirano T, Kishimoto T. Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution and regulation of their expression. J Exp Med 1987;166:967–981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Tominaga T, Yamashita S, Nagayama Y, et al. Interleukin 6 inhibits human thyroid peroxidase gene expression. Acta Endocrinol (Copenh) 1991;124:290–294. [DOI] [PubMed] [Google Scholar]
  • 21. Tsukamoto K, Haruta K, Shiba T, Emi M. Isolation and mapping of a polymorphic CA repeat sequence at the human interleukin 6 locus. J Hum Genet 1998;43:71–72. [DOI] [PubMed] [Google Scholar]
  • 22. Chapman CM, Beilby JP, Humphries SE, Palmer LJ, Thompson PL, Hung J. Association of an allelic variant of interleukin‐6 with subclinical carotid atherosclerosis in an Australian community population. Eur Heart J 2003;24:1494–1499. [DOI] [PubMed] [Google Scholar]
  • 23. Dao DD, Sawyer JR, Epstein J, Hoover RG, Barlogie B, Tricot G. Deletion of the retinoblastoma gene in multiple myeloma. Leukemia 1994;8:1280–1284. [PubMed] [Google Scholar]
  • 24. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin‐6 (IL‐6) gene on IL‐6 transcription and plasma level, and an association with systemic‐onset juvenile chronic arthritis. J Clin Invest 1998;102:1369–1376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Tsukamoto K, Ohta N, Shirai Y, Emi M. A highly polymorphic CA repeat marker at the human tumor necrosis factor alpha (TNFA alpha) locus. J Hum Genet 1998;43:278–279. [DOI] [PubMed] [Google Scholar]
  • 26. Blakemore AI, Watson PF, Weetman AP, Duff GW. Association of Graves' disease with an allele of the interleukin‐1 receptor antagonist gene. J Clin Endocrinol Metab 1995;80:111–115. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES